This is a blend. Ipamorelin and DSIP are combined in a single 10 mg vial, 5 mg of each. The two are studied in different literatures: Ipamorelin is a five amino acid growth hormone secretagogue that binds GHS-R and is studied for release selectivity, while DSIP is a nine amino acid neuropeptide first isolated in 1977 and studied for brain wave patterns and sleep timing. The combination has not been characterised as a single formulation.
The numbers that define Ipamorelin / DSIP and how it is being studied. For laboratory research use only.
2
Research Peptides
Ipamorelin · DSIP
10 mg
Total Per Vial
5 mg of each component
GHS-R
Ipamorelin Target
Secretagogue receptor
4
Research Areas
GH pulse studies
Sleep architecture
Stress response
How It Works
How Ipamorelin / DSIP works
The pathways Ipamorelin / DSIP acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
GHS-R Binding
Ipamorelin
Ipamorelin binds GHS-R, the growth hormone secretagogue receptor. Selectivity is the main point of study: compared with older compounds in the same class it shows little effect on cortisol, prolactin and ACTH.
GHS-R1a agonist
Growth hormone release endpoints
Selectivity vs older secretagogues
Unresolved Receptor
DSIP
DSIP was first isolated in 1977 from blood drawn during deep sleep. Brain wave patterns, sleep timing and stress hormone response have been measured, but after nearly fifty years no receptor has been identified.
Nine amino acid neuropeptide
Sleep timing endpoints
Mechanism still unresolved
Two Literatures
Combined
The vial pairs a receptor-defined secretagogue with a neuropeptide whose receptor is unknown. The two are characterised separately and no interaction data exists for the pair.
Endocrine and neuro arms
Matched handling
Interaction not characterised
Uses & Applications
What Ipamorelin / DSIP is researched for
The main areas Ipamorelin / DSIP is being studied for - and the study-reported figures behind them.
Endocrine
GH Pulse Studies
Ipamorelin is characterised for growth hormone release and class selectivity.
Neuro
Sleep Architecture
DSIP has been measured for brain wave patterns and sleep timing.
Endocrine
Stress Response
Both peptides appear in stress hormone literature from different directions.
Methods
Parallel Protocols
One vial holds both peptides under matched handling.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
Ipamorelin GHS-R SelectivityWell characterised
DSIP Sleep EndpointsMeasured
DSIP Receptor IdentityUnresolved
Blend Interaction DataNone
Figures are representative of published research findings and shown for reference.
Molecular Structure
The Ipamorelin / DSIP molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
Sequence length
blend
Physical form
Lyophilized powder blend
Documented purity
≥99% by HPLC
Compound Information
Full specification
Components
Ipamorelin + DSIP
Content
10 mg per vial (5 mg of each component)
Ipamorelin
Aib-His-D-2-Nal-D-Phe-Lys-NH₂, CAS 170851-70-4
DSIP
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, CAS 62568-57-4
Form
Lyophilized powder blend
Purity
≥99% by HPLC
Appearance
White to off-white powder
Solubility
Water-soluble
Storage
-20°C, protected from light
Classification
Research use only
FAQ
Common questions about Ipamorelin / DSIP
They come from two different literatures that overlap in circadian and endocrine research: Ipamorelin through GHS-R binding and growth hormone release, DSIP through sleep timing and stress hormone endpoints. One vial holds both under matched handling.
No. DSIP has been studied since 1977 and its endpoints are documented, but no receptor has been identified and the mechanism remains unresolved.
No. Each peptide is characterised separately and no interaction data exists for the pair.
The separate products let you control each peptide quantity independently. This vial fixes the ratio at 5 mg and 5 mg.
Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
